NASDAQ:ARDS - Aridis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.67
  • Forecasted Upside: 408.18 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.87
▲ +0.13 (3.48%)

This chart shows the closing price for ARDS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aridis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARDS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARDS

Analyst Price Target is $19.67
▲ +408.18% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aridis Pharmaceuticals in the last 3 months. The average price target is $19.67, with a high forecast of $22.00 and a low forecast of $18.00. The average price target represents a 408.18% upside from the last price of $3.87.

This chart shows the closing price for ARDS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Aridis Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/20/2021HC WainwrightBoost Price TargetPositive ➝ Buy$11.00 ➝ $19.00High
4/9/2021HC WainwrightReiterated RatingBuyLow
2/24/2021Northland SecuritiesReiterated RatingBuy$22.00High
2/23/2021Roth CapitalReiterated RatingBuyMedium
1/22/2021Roth CapitalReiterated RatingBuy$18.00High
12/7/2020Northland SecuritiesReiterated RatingBuy$22.00High
11/23/2020Northland SecuritiesReiterated RatingBuy$22.00High
8/13/2020Maxim GroupReiterated RatingBuy$17.00Low
6/23/2020Maxim GroupReiterated RatingBuy$17.00High
5/15/2020HC WainwrightReiterated RatingPositive ➝ Buy$7.00 ➝ $11.00High
5/5/2020Maxim GroupInitiated CoverageBuy$17.00High
4/10/2020Maxim GroupInitiated CoverageBuy$17.00High
4/9/2020Northland SecuritiesReiterated RatingBuy$22.00High
2/19/2020Roth CapitalInitiated CoverageBuy$18.00High
12/30/2019HC WainwrightInitiated CoverageBuy$7.00High
11/14/2019Northland SecuritiesReiterated RatingBuy$22.00Low
9/30/2019Northland SecuritiesSet Price TargetBuy$22.00Low
9/4/2019LaidlawSet Price TargetBuy$15.00Low
9/3/2019Maxim GroupSet Price TargetBuy$25.00Low
8/15/2019Maxim GroupReiterated RatingBuy$25.00High
8/13/2019Northland SecuritiesReiterated RatingBuy$40.00High
7/31/2019Maxim GroupReiterated RatingBuyHigh
7/30/2019Northland SecuritiesReiterated RatingBuy$40.00High
5/16/2019Maxim GroupSet Price TargetBuy$25.00Low
4/17/2019Northland SecuritiesReiterated RatingBuy$40.00Low
4/1/2019Maxim GroupReiterated RatingBuy$25.00High
3/29/2019Northland SecuritiesReiterated RatingBuy$40.00Low
1/9/2019Cantor FitzgeraldReiterated RatingBuy$25.00Medium
12/26/2018Cantor FitzgeraldReiterated RatingBuy$25.00High
12/12/2018Maxim GroupSet Price TargetBuy$25.00Low
12/4/2018Maxim GroupSet Price TargetBuy$25.00Low
11/13/2018Cantor FitzgeraldReiterated RatingBuy$25.00Low
11/13/2018Maxim GroupSet Price TargetBuy$25.00Low
10/2/2018Maxim GroupInitiated CoverageBuyMedium
9/10/2018Northcoast ResearchInitiated CoverageOutperform$40.00Low
9/10/2018Northland SecuritiesInitiated CoverageOutperformLow
9/10/2018LaidlawInitiated CoverageBuy$23.00Low
9/10/2018Cantor FitzgeraldInitiated CoverageOverweightLow
9/9/2018Cantor FitzgeraldInitiated CoverageBuy$25.00Low
(Data available from 9/24/2016 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Aridis Pharmaceuticals logo
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in Los Gatos, CA.
Read More

Today's Range

Now: $3.87
Low: $3.76
High: $4.01

50 Day Range

MA: $4.30
Low: $3.59
High: $5.85

52 Week Range

Now: $3.87
Low: $3.54
High: $8.50

Volume

38,508 shs

Average Volume

75,174 shs

Market Capitalization

$46.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Aridis Pharmaceuticals?

The following Wall Street analysts have issued reports on Aridis Pharmaceuticals in the last twelve months: HC Wainwright, Northland Securities, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for ARDS.

What is the current price target for Aridis Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Aridis Pharmaceuticals in the last year. Their average twelve-month price target is $19.67, suggesting a possible upside of 408.2%. Northland Securities has the highest price target set, predicting ARDS will reach $22.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $18.00 for Aridis Pharmaceuticals in the next year.
View the latest price targets for ARDS.

What is the current consensus analyst rating for Aridis Pharmaceuticals?

Aridis Pharmaceuticals currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARDS will outperform the market and that investors should add to their positions of Aridis Pharmaceuticals.
View the latest ratings for ARDS.

How do I contact Aridis Pharmaceuticals' investor relations team?

Aridis Pharmaceuticals' physical mailing address is 5941 Optical Ct, San Jose CA, 95138. The company's listed phone number is (408) 385-1742 and its investor relations email address is [email protected] The official website for Aridis Pharmaceuticals is www.aridispharma.com.